

Technology Appraisal Committee D Interests Register

Topic: Ruxolitinib for treating polycythaemia vera - review of TA356 [ID5106]

Publication Date: 18/10/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Chris Parker	Committee member	Non-Financial Professional	Professor Parker is a Chief Investigator of a trial of PSMA-Lutetium in prostate cancer, sponsored by the MRC, funded by Novartis.	20.04.2023	It was agreed that his declarations would not prevent Professor Parker from participating in discussions on this appraisal.
Professor David Meads	Committee member	Non-Financial Professional	University of Leeds has received funding from BMS and Takeda for research in an unrelated area.	19.04.2023 & 30.06.2023	It was agreed that his declarations would not prevent Professor Meads from participating in discussions on this appraisal.
Professor Claire Harrison	Clinical expert	Direct & indirect financial	Professor Harrison has received fees for Advisory boards/data monitoring from Novartis, BMS/Celgene, CTI, Gilead, Shire, Roche, Janssen, Promedior, Geron, Galacteo, AOP, Keros, Sierra and	04.08.2022 & 12.07.2023	It was agreed that her declarations would not prevent Professor Harrison from providing expert advice to committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			research funding from Novartis, BMS/Celgene, Constellation.		
Professor Tim Somervaille	Clinical expert	Direct financial	Professor Somervaille has received fees for provided consulting services for Novartis & BMS intermittently over the last 5-10 years in view of his clinical expertise in the myeloproliferative disorders.	05.08.2022 & 12.07.2023	It was agreed that his declarations would not prevent Professor Somervaille from providing expert advice to committee.